HWP
BMRN icon

Hibernia Wealth Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hibernia Wealth Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-9
Closed -$796 – 97
2023
Q3 		$796 Buy
+9
New +$801 ﹤0.01% 300

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Hibernia Wealth Partners's BMRN Position: Q4 2023 in Review

Hibernia Wealth Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 9 shares — an estimated $796 sold.

Hibernia Wealth Partners first reported a position in BMRN in Q3 2023 and held it in 1 quarter. The position peaked at $796 in Q3 2023. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

  • Hibernia Wealth Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Hibernia Wealth Partners sold 9 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $796.
  • Hibernia Wealth Partners first reported a position in BioMarin Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Hibernia Wealth Partners's BioMarin Pharmaceuticals position peaked at $796 in Q3 2023.
  • 547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Hibernia Wealth Partners's 13F filing for Q4 2023, filed 19 Jan 2024.